论文部分内容阅读
目的 观察消旋山莨菪碱控制儿童近视增长的效果.方法 2015年1月至2016年1月门诊确诊为轻度近视的儿童,在征得患者及家属理解同意后分为单纯配镜、配镜联合使用阿托品、配镜联合使用消旋山莨菪碱三组,各组均60例,其年龄、治疗前屈光度、眼轴长度、眼压均无统计学差异.1年后对三组儿童的等效屈光度、眼轴长度、眼压等指标进行统计学分析.结果 治疗后,等效屈光度变化量、眼轴长度变化量、眼压变化量在阿托品组分别为-0.02±0.10D、0.09±0.08mm、0.09±1.16mmHg;在消旋组分别为-0.52±0.14D、0.38±0.10mm、0.13±1.12mmHg;单纯配镜对照组分别为-1.01±0.17D,0.96±0.14mm、0.08±1.08mmHg.等效屈光度变化量、眼轴长度变化量三组间两两比较均有统计学差异,0.05.结论 消旋山莨菪碱能有效控制儿童近视进展,但控制效果较阿托品弱.“,”Objective To investigate the effect of racanisodamine on myopia progression in children. Methods With the understanding and agreement of the patients and their families, mild myopia patients from January 2015 to Jan-uary 2016 were divided into three groups: glasses, glasses combined with atropine and glasses combined with racaniso-damine. Each group has 60 patients with no statistical differences in age, spherical equivalent (SE),axial length(AL)be-fore treatment. Subjects were followed up for one year. Results 1 year later, The average progression of SE, AL and IOP were -0.02 ±0.10D、0.09 ±0.08mm、0.09 ±1.16mmHg for the atropine group, and -0.52 ±0.14D、0.38 ±0.10mm、0.13 ± 1.12mmHg for the anisodamine group, and -1.01±0.17D,0.96±0.14mm、0.08±1.08mmHg for the control group respec-tively. There exsit statistical differences in SE and AL but no in IOP between each two groups. Conclusion Racaniso-damine can control the progression of myopia in children, but the effect is weaker than atropine.